Compare Neurocrine Biosciences Inc (NBIX) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Occidental Petroleum Corporation — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Occidental Petroleum Corporation trades at $59.86 (market cap $60.26B). The key difference: Occidental Petroleum Corporation is far larger — about 4.2× Neurocrine Biosciences Inc's market cap, and Occidental Petroleum Corporation pays a 1.86% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Occidental Petroleum Corporation for 92 Days on average.
| NBIX | OXY | |
|---|---|---|
Market Cap | $14.36B | $60.26B |
Volume | 1,237,180 | 11,718,920 |
Sector | Health | Energy |
52-Week High | $185.50 | $66.24 |
52-Week Low | $123.10 | $38.92 |
Typical Hold Time | 23 Days | 92 Days |
Enterprise Value | $14.37B | $79.02B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Occidental Petroleum (OXY) trades at $58.21, down 0.21% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a 30.32% net income margin and 21.46% ROE, while valuation metrics appear reasonable with a P/E of 17.17 and EV/EBITDA of 5.42. Recent earnings have consistently beaten expectations, and the company maintains a solid balance sheet with $2.13 billion in cash. Analyst consensus is bullish with a $71.40 price target, and the upcoming Q3 2026 earnings report on November 9 is a key catalyst.
OXY presents a compelling investment case with strong fundamentals, reasonable valuation, and positive analyst sentiment. The primary opportunities include continued earnings outperformance, debt reduction progress, and carbon management initiatives. Key risks include oil price volatility, declining revenue trends from $36.6B in 2022 to $21.6B in 2025, and execution challenges in the competitive energy sector. The stock offers upside potential to analyst targets but remains sensitive to commodity price movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
